80890-07-9

Basic information

• Product Name: (R)-Nitrendipine
• Synonyms: (+)-(R)-Nitrendipine;(R)-(+)-Nitrendipine;(R)-Nitrendipine;3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (4R)- (9CI);3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester, (R)-;(R)-2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-methyl 5-ethyl ester;[R,(+)]-2,6-Dimethyl-4β-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-methyl 5-ethyl ester;PVHUJELLJLJGLN-MRXNPFEDSA-N
• CAS NO: 80890-07-9
• Molecular Formula: C₁₈H₂₀N₂O₆
• Molecular Weight: 360.36
• Product Categories: Aromatics, Heterocycles, Miscellaneous Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 80890-07-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 488.9°C at 760 mmHg
• Flash Point: 249.5°C
• Appearance: /
• Density: 1.247g/cm³
• Vapor Pressure: 1.04E-09mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: (R)-Nitrendipine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Nitrendipine(80890-07-9)
• EPA Substance Registry System: (R)-Nitrendipine(80890-07-9)

Safety Data

• Hazardous Substances Data: 80890-07-9(Hazardous Substances Data)

Usage

Uses

(+)-Nitrendipine is used in the treatment of hypertension for the regulation of blood pressure. A dihydropyridine calcium channel blocker.

InChI:InChI=1/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3/t16-/m1/s1

Upstream product

• 39562-70-4 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid ethyl methyl ester 

Downstream Products

• 138135-46-3 (R)-2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-((2S,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxy-tetrahydro-pyran-2-yl) ester 5-methyl ester 

Relevant articles and documents

Enantioselective retention of 4-aryl-1,4-dihydropyridine calcium-channel blockers on human serum albumin and α1-acid glycoprotein HPLC columns: Relationships with different scales of lipophilicity

The enantioselective retention of eight 4-aryl-1,4-dihydropyridine (DHP) calcium-channel blockers on HPLC stationary phases supporting human serum albumin (HSA) or α1-acid glycoprotein (AGP) was investigated. All chiral neutral DHPs were resolved on the AGP column, whereas, on the HSA column, only isradipine showed a split chromatographic peak. Analyses performed on AGP with eluents containing dimethyloctylamine (DMOA) as thc displacer demonstrated that the protein has at least two binding sites for DHPs. The first family of binding sites is enantioselective, binds exclusively to the (R)-forms, and presumably interacts competitively with DMOA. The second family of binding sites appears to be non-enantioselective and is affected by a cooperative interaction with DMOA. For the selected set of DHPs, the lipophilicity scale in octan-1-ol/H2O (log P) was not collinear with log k(w)(IAM) values obtained with immobilized artificial membranes (IAM-HPLC) due to the inclusion of both neutral and basic congeners. Only for the neutral DHPs did log k(w)(IAM) behave as a better descriptor than log P for retention date on HSA and AGP. In fact, the behavior of the basic DHPs amlodipine and nicardipine on both proteins correlated better with the octan- 1-ol/H2O log P values. We, therefore, infer that the amphipathic nature of the IAM phase only mimics the interaction of non-ionizable compounds with serum proteins. In contrast, the IAM-HPLC retention data of protonated bases encode additional interaction mechanisms that are specific for phospholipids and not involved in ligand-protein interactions.